Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma
Genes, Chromosomes and Cancer · 2024-05 · 63 (5)
DOI: 10.1002/gcc.23240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 09.05.2024. Verfasst von Hsin-Yi Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hemangiosarcoma, Neoadjuvant Therapy, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Both primary and secondary breast angiosarcoma (AS) are characterized by multifocal presentation and aggressive behavior. Despite multimodality therapy, local and distant relapse rates remain high. Therefore, neoadjuvant chemotherapy (NACT) is employed to improve the R0 resection rates and survival, but its benefits remain controversial. Herein, we investigate pathologic and molecular correlates to NACT‐induced histologic response in a group of 29 breast AS, 4 primary and 25 radiation‐associated (RA). The two NACT regimens applied were anthracycline‐ and non‐anthracycline‐based. The pathologic response grade was defined as: I: ≤ 50%, II: 51%–90%, III: 91%–99%, and IV: 100%. An additional 45 primary AS and 102 RA‐AS treated by surgery alone were included for survival comparison. The genomic landscape was analyzed in a subset of cases and compared to a cohort of AS without NACT on a paired tumor‐normal targeted DNA NGS platform. All patients were females, with a median age of 31 years in primary AS and 68 years in RA‐AS. All surgical margins were negative in NACT group. The NACT response was evenly divided between poor (Grades I–II; n = 15) and good responders (Grades III–IV; n = 14). Mitotic count >10/mm 2 was the only factor inversely associated with pathologic response. By targeted NGS, all 10 post‐NACT RA‐AS demonstrated MYC amplification, while both primary AS harbored KDR mutations. TMB or other genomic alterations did not correlate with pathologic response. All four patients with Grade IV response remained free of disease. The good responders had a significantly better disease‐specific survival ( p = 0.04). There was no survival difference with NACT status or the NACT regimens applied. However, NACT patients with MYC ‐amplified tumors showed better disease‐free survival ( p = 0.04) compared to MYC ‐amplified patients without NACT. The overall survival of NACT group correlated with size >10 cm ( p = 0.02), pathologic response ( p = 0.04), and multifocality ( p = 0.01) by univariate, while only size >10 cm ( p = 0.03) remained significant by multivariate analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Surgery, Gastric Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Surgery, Weill Cornell Medical Center, New York, New York, USA.
- Department of Medicine, Sarcoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Cristina R Antonescu
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- Cycle for Survival
Zitieren
APA
Chang, H. Y., Dermawan, J. K., Kuba, M. G., Crago, A. M., Singer, S., Tap, W., Chi, P., D'Angelo, S., Rosenbaum, E., & Antonescu, C. R. (2024). Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma. Genes, Chromosomes and Cancer, 63(5). https://doi.org/10.1002/gcc.23240
Vancouver
Chang HY, Dermawan JK, Kuba MG, Crago AM, Singer S, Tap W, et al. Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma. Genes, Chromosomes and Cancer. 2024;63(5). doi:10.1002/gcc.23240
BibTeX
@article{Chang2024,
author = {Chang, Hsin-Yi and Dermawan, Josephine K and Kuba, Maria Gabriela and Crago, Aimee M and Singer, Samuel and Tap, William and Chi, Ping and D'Angelo, Sandra and Rosenbaum, Evan and Antonescu, Cristina R},
title = {Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma},
journal = {Genes, Chromosomes and Cancer},
year = {2024},
volume = {63},
number = {5},
doi = {10.1002/gcc.23240}
}
EUVIMED